Pharmacology Biochemistry and Behavior, Vol. 43, pp. 1279–1287, 1992
Printed in the U.S.A. All rights reserved.

0091-3057/92 $5.00 + .00
Copyright © 1992 Pergamon Press Ltd.

SUBJECT INDEX

Aberrant drinking, 661
Abuse liability, 563
Abused drugs, 357
Acetylcholine, 139, 617, 635, 645, 657, 1201
Acetylsalicylic acid, 1169
ACTH, 85, 315
Activated charcoal, 621
Active avoidance, 139
Activity, 1023
Acute, 765
Acute dependence, 1093
Acute intoxication, 641
Adaptation, 597, 765
Adenosine, 117
Adenosine deaminase, 117
Adenosine receptors, 117
Adenylate cyclase, 139
Adrenaline synthesis inhibitors, 985
Adrenergic receptor: α_2, dexmedetomidine, 723
Adult rat, 881
Affect, 377
Ageing, 341
Aging, 117, 1005
Alcohol, 103, 563, 589, 1233
Alcohol dehydrogenase, 1071
Alcohol drinking, 661
Alcohol preference, 103, 661
Alcohol-preferring rats, 103
Alcoholism, 661
α_2-adrenoceptor(s), 697, 733, 1129
α-helical CRF, 37
α-methyl-*p*-tyrosine, 597
α_2-noradrenergic receptors, 1039
α_2-receptors, 733
α-tocopherol, 1175
Alternation, 1161
Aluminum salts, 271
Alzheimer's disease, 635
Ambulation, 125
Amiloride, 271
Amino acid changes, 205
Amino acids, 205
Amperozide, 661
Amphetamine(s), 1, 329, 347, 705, 749, 795, 815, 887, 1023, 1047, 1075, 1099, 1117, 1151, 1247
Amygdala, 315, 453, 503
Analgesia, 855, 925, 1129
Analgesic effect, 187
Anesthetic, 523
Angiotensin II, 229, 729, 1143
Animal behavior, 263
Aniracetam, 1161
Anorexia, 733, 847, 943
ANP, 193
Antagonism, 111, 1023
Antagonism by morphine or naloxone of glutamate, 479
Anticholinergic drugs, 645
Anticonvulsants, 441
Antidepressives, 549
Antinociceptive, 1129
Antipsychotic(s), 369, 961
Anxiety, 77, 153, 167, 181, 433, 453, 471, 529, 631, 677, 825, 855, 1195
Anxiety disorders, 263
Anxiety/fear, 729
Anxiolytics, 85, 453, 471, 697
Apomorphine, 329, 705, 887
Arousal, 347
Ascorbic acid, 1175
A68552, 369
Associations, 907
Astringency, 271
Attenuation of morphine physical dependence, 341
Attenuation of precipitated abstinence syndrome, 487
Autogrooming, 855
Autoradiography, 441
Aversive conditioning, 205
Avoidance, 369, 1155

Baseline activity, 495
BDZ binding, 825
Behavior, 243, 449, 785, 825, 871
Behavioral impairment, 807
Behavioral sensitization, 491
Benzodiazepine(s), 153, 321, 413, 453, 677, 825, 1195
Benzodiazepine-$GABA_A$ receptor complex, 677
Benzodiazepine receptors, 77, 583
Benzyl alcohol, 1071
β-adrenoceptor agonist, 1143
β-adrenoceptor antagonists, 985
β-carbolines, 77
B-HT 920, 993
Bicuculline, 297
Black bear, 199
Blastogenic response, 85
Blood alcohol concentration, 641
Blood-brain barrier, 939
Blood pressure, 1047
Body composition, 641
Body mass index, 641
Body size, 263
Body temperature, 103, 825, 993
Body water, 641
Body weight, 263, 897
Bombesin, 957
Brain, 523, 881, 939
Brain damage, 785
Brain injury, 771
Brain regions, 395
Brain stem, 925
Brain-stimulation reward, 1
Branched-chain amino acids, 669
Breath holding, 907
Breathing, 1227
Brown adipose tissue, 577
Buspirone, 167, 739, 961
Butorphanol, 1129

Caffeine, 513, 815
CAI, 1201
Calcitonin gene-related peptide, 1107
Calcium channel blockade, 1023
Calcium channels, 1093
cAMP, 1107
Camphor odor, 417
Cannabinoids, 381
Cannabis, 1227
Carbachol, 1201
Carbamazepine, 453
Carbon monoxide, 907
Cat, 1269
Cat odor, 1195
Catalepsy, 381, 999
Catecholamines, 597
Cathinone, 1023
Caudate, 1075
Caudate putamen, 17, 887
CCK, 369
CCK-8, 571
CCK_A receptors, 943, 975, 943
Central adrenergic neurons, 985
Ceruletide, 571
C57BL/6J mice, 285
C57Bl/6J, 1039
C57 mice, 625
CGS 10746B, 1023
Chain manipulation, 347
Chloral hydrate anesthesia, 929
Chlordiazepoxide, 453
Choice, 463
Cholecystokinin, 369, 943, 979
Cholecystokinin antagonists, 613, 975
Choline precursors, 139
Cholinergic neurons, 645
Cholinergic system, 91, 673
Cholinesterase inhibitor, 985
Chronic, 765
Chronic OT, 855
Chronic stress, 597
CI 988, 613

Circadian rhythm(s), 159, 549, 979
Clomipramine, 549
Clonidine, 697, 733, 1039, 1093
Clorgyline, 1075
Clozapine, 369, 961
CNS depression, 297
CNS stimulants, 967
Cocaine, 45, 111, 235, 243, 395, 491, 509, 613, 631, 815, 871, 929, 1015, 1023, 1135
Cocaine HCl, 1059
Cocaine pharmacokinetics, 45, 235
Coffee, 513
Cognition, 907
Cold resistance, 117
Colonic temperature, 229
Compulsive behavior, 329
Conditioned activation, 307
Conditioned compensatory response, 1263
Conditioned defensive burying, 729
Conditioned place preference, 97, 377, 1015, 3076
Conditioned reward, 377
Conditioned taste aversions, 839
Conditioned tolerance, 1263
Conditioning, 887
Conflict, 503
Conflict behavior, 453, 471, 697
Continuous reinforcement schedule, 589
Convulsants, 441
Convulsions, 1165
Corpus striatum, 705
Corticosteroid, 315
Corticosterone, 897
Corticosterone levels, 537
Cortisol, 37
CRF, 37
Crickets, 205
Crocodilia, 449
Cross-tolerance, 187
CSF calcium, 1253
Cyclic adenosine monophosphate, 603
Cyclophosphamide, 315
Cysteamine, 1165

D_1, 377
d-amphetamine, 249, 689, 967
D_1 and D_2 dopaminergic receptors, 603
d-AP159, 503
DA receptors, 967
DA uptake, 967
DBA/2J, 97
D-cycloserine, 609
Defecation, 125
Defensive burying behavior, 453
Dehydroepiandrosterone, 223
Dehydroepiandrosterone sulfate, 223
Delayed spatial alternation, 1151
Δ^9-tetrahydrocannabinol, 61, 907
Dentate gyrus, 1201
Deoxycorticosterone acetate, 229
Dependence, 193, 799
Deprenyl, 1075
Depression, 1
Desensitization, 405
Desipramine, 549
Devazepide, 613, 943
Developmental toxicity, 1059
Dexamethasone, 1081
d-fenfluramine, 173
Dialysis, 17
Diazepam, 153, 181, 361, 387, 433, 463, 689
Digiscan monitoring system, 807
Dilazep, 673
Dipsogenic agents, 1143
Discrimination, 111, 1117
Disinhibition, 657
Dissociative anesthesia, 1129
Dissociative effect, 1269
Dizocilpine, 785
Dog(s), 263, 749
DOI, 765, 1273
DOM, 1099, 1221
Dopamine, 1, 17, 249, 377, 395, 423, 495, 603, 617, 887, 929, 967, 979, 1023, 1075, 1087, 1099, 1135, 1151, 1217
Dopamine antagonist, 863
Dopamine autoreceptors, 53
Dopamine D_1 and D_2 receptors, 993
Dopamine metabolism, 53
Dopamine transporter, 871
Dopaminergic system(s), 661, 673
Dorsal immobility response, 303
Dorsal raphe, 503
Dorsal striatum, 303
Dose-addition, 61
D_2 receptor(s), 71, 863, 1217
Drinking, 329, 689
Drinking behavior, 103
Drug discrimination, 77, 583, 613, 739, 759, 961, 967, 1099, 1233
Drug discrimination learning, 839
Drug interactions, 61
Drug preference, 563
Drug self-administration, 45, 235
Drug tolerance, 807
Drug-admixed food method, 387
DSIP, 683
DSP4, 697
Duodenum, 919
DuP 753, 229

Ear-scratch response, 765
Eating, 1033
Effect-addition, 61
8-hydroxy-2-(di-*n*-propylamino)tetralin, 405
8-OH-DPAT, 1273
Elevated plus-maze, 529, 631, 677
Energy balance, 897
Enkephalin, 187
Entorhinal cortices, 315
Entrainment, 159
Environment size, 1217
Ephedrine, 1047
Epilepsy, 529, 651, 1269
Error responding, 657
Escapable stress, 361
Escape, 1155
Estradiol, 303
Ethanol, 61, 97, 159, 223, 285, 297, 307, 625, 661, 683, 939, 1121, 1233, 1263
Ethanol drinking, 1071
Ethanol reinforcement, 249
Ethanol withdrawal, 1169
Ethylcocaine, 509
Excessive drinking, 347
Excitatory amino acid antagonist, 807
Exercise, 285, 733
Experimental allergic encephalomyelitis, 1081
Exploration, 529, 847, 1183, 1247

Fascia dentata, 785
Fawn-hooded rats, 103
Feeding, 825, 847, 919, 943, 1039
Feeding behavior, 881, 897
Female rats, 953
Females, 1005
Fertility, 449
Fetus, 1227
Fever, 1253
Fever conditioning, 417
FG 7142, 77, 1247
Fischer 344 rat, 387
5-HT, 739
5-HT_{1A}, 503
5-HT_2, 1099
5-HT_3, 1099
5-HT_3 antagonists, 871
5-HT_{1A}-anxiolytics, 433
5-HT_1/β-blockers, 433
5-HT_{1A} receptors, 131, 405
5-HT_2 receptors, 131
5-HT receptor subtypes, 739
5-hydroxytryptamine, 847
5-hydroxytryptophan, 173
5,7-DHT lesion, 503
5,7-dihydroxytryptamine, 1247
Fixed-consecutive-number schedule, 61
Fixed-ratio schedule, 111
Flumazenil, 433
Fluoxetine, 549
Food deprivation, 897, 957
Food intake, 733, 975, 1033
Food reward, 863
Forced swim test, 597
Frontal cortex, 361

GABA, 223, 297, 321
$GABA_A$, 1121
GABA-benzodiazepine receptor complex, 669
GABAergic system, 91
GABA-5-HT interactions, 433
π-vinyl-GABA, 91
Gastric ulceration, 1053
Gastrointestinal absorption, 939
Gastrointestinal dialysis, 621
GBR12909, 1135
Gender differences, 263
General anesthesia, 523
Generalization, 839
Genetic difference(s), 387, 549
Genetic obesity, 1039
Genotype, 53
Glucose transport, 919
Glycemia, 919
Glycine, 609
Glycosuria, 919
G proteins: G_{0a}, $G_{ia1,2}$, G_{ia3}, 723
Ground squirrel, 199
Growth, 263
Guinea pig, 37
Guinea pig ileum, 199
Gustation, 513
Gut peptides, 975

Habituation, 1183
HAD, 1233
Haloperidol, 1, 369, 617, 961
Hamster(s), 979, 1093
Headslap display, 449
Heart rate, 357
Heat, 1065

Heat exchange, 1209
Hepatic-portal vein, 919
Heroin, 187
Hibernation, 199
Hibernation induction trigger, 199
High and low activity, 631
Hippocampus, 71, 167, 785, 1201, 1269
Hole board, 529, 597
HPLC, 395
Humans, 463, 513, 563
Humoral immunity, 537
Hyperactivity, 1217
Hyperalgesia, 925
Hyperhydration, 1143
Hypermotility, 491
Hyperphagia, 881
Hypnosis, 223
Hypnotic, 413
Hypoalgesia, 321
Hypoglycemia, 957
Hypothalamus, 897
Hypothermia, 173, 223, 405, 957, 1263

Ibogaine, 1221
Ibotenic acid, 705
ICSS, 657
ICS-205,930, 1241
Idazoxan, 77
Imipramine, 361
Immobilization, 597
Immunity, 85
Immunofacilitation, 1081
Inbred mice (DBA/2J), 97, 307
Inbred strains, 549
Incentive motivation, 863
Independent ingestion, 863
Individual differences, 347, 563, 815
Indomethacin, 417
Induced seizures, 621
Inescapable stress, 361
Inhibitory stimulus control, 589
Inositol phosphate, 139
Insects, 205
Insulin-like growth factor-I/somatomedin C, 263
Intensification of morphine dependence, 487
Intensification of morphine physical dependence, 341
Intracerebroventricular, 1023
Intracranial self-stimulation, 495
Intraoral catheter, 863
In vivo electrochemistry (voltammetry), 929
Ionizing radiation, 785
Iowa Tests, 907
Isolation, 37
Isolation rearing, 17
Isoproterenol, 1143
Isradipine, 1023
I2CA, 609

Jugular vein, 919

Ketanserin, 765
Kindling, 807, 1269
Kynurenic acid, 807

LAD, 1233
L-deprenyl, 749
LDL oxidation: initiation and propagation, 1175
Learned helplessness, 361
Learning, 71, 205, 215, 907
Learning and memory, 1005
Learning block, 417
Left-right discrimination, 1151
L-erythro-DOPS, 215
Levoprotiline, 549
Lewis rat, 387
LHRH, 1005
Licking, 1217
Limbic seizures, 315, 1081
Limbic system, 683
Lithium, 315, 1081
Liver, 919, 1071
Location preferences, 125
Locomotion, 53, 329
Locomotor activity, 17, 45, 97, 307, 529, 779, 807, 815, 887, 979, 1015, 1053, 1135, 1183, 1247
Locus coeruleus, 255, 723, 771
Long-term memory, 205
Lordosis, 833
Losartin potassium, 229
Loss of righting reflex, 297
Loss of righting response, 285
LSD, 1221
L-threo-DOPS, 215
Lu 10 171 (citalopram), 483
LY163502, 1087
LY 278584, 1099

Macronutrient selection, 1039
Maharishi Amrit Kalash-4, 1175
Maharishi Amrit Kalash-5, 1175
Maharishi Ayur-Veda, 1175
Maharishi Coffee Substitute, 1175
Marijuana, 907, 1227
MA-631, 1175
Mast cells, 1053
Maternal separation, 37
MDL 72222, 961, 1233
MDMA, 759, 1099
MDMA metabolites, 759
Medial frontal cortex, 815
Medial prefrontal cortex, 887
Medial preoptic area, 1087
Memory, 205, 907
Memory consolidation, 205
Memory storage, 617
Mesolimbic system structures, 661
Metabolites, 395
Methadone, 1033
Methamphetamine, 759
Methionine sulfoximine, 173
Methiothepine, 483
Methodology, 381
Methylation, 4523
Methysergide, 1241
Met^2-pro^3-enkephalinamide, 187
Metoclopramide, 967
Metrazol, 315
Mice, 181, 369
Microinjection, 503
Microstructure, 1121
Midazolam, 85
Milacemide, 609
MK 801, 291, 471, 487, 609, 785, 1269
Moclobemide, 549
Mongolian gerbil, 131
Monoamine oxidase, 1075
Monoamines, 395, 683
Monosodium glutamate, 341, 881
Morphinans, 651
Morphine, 193, 479, 603, 799, 1093
Morphine-dependent guinea pig ileum, 479
Morphine-like effect of naloxone, 479
Morris water maze, 949
Motivation, 377
Motor activity, 111, 625, 705
Motor behavior, 173
Mouse, 395, 571
Multivariate assessment, 807
Muscarinic effects, 1081
Muscarinic receptors, 617

Naloxone, 1, 321, 357, 479, 1065, 1093, 1183, 1065
Neostigmine, 125
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, 405
Neural development, 291
Neuroleptics, 961
Neuromodulation, 205
Neurosteroid, 223
Neurotoxicity, 621, 881
Nicotine, 779, 1053
Nicotine abstinence, 779
Nicotine dependence, 779
Nicotine withdrawal, 779
Nicotinic receptors, 1165
Nifedipine, 1093
Nile crocodile, 449
NK conditioning, 417
NMDA, 297, 651, 1269
NMDA antagonist, 471
NMDA receptor blockade, 479
NMDA receptor complex, 609
Nociception, 799, 925
Nomifensine, 1135
Nonpeptide angiotensin II receptor antagonist, 229
Nonphotic zeitgebers, 159
Nonshivering thermogenesis, 577
Nonsteroidal antiinflammatory drugs, 1169
Nootropic drugs, 949, 1161
Noradrenaline, 215
Norepinephrine, 77, 395, 577, 697, 771
Novelty, 125, 815, 1183
Nucleus accumbens, 17, 249, 815, 887
Nutritional pharmacology, 669

ob/ob, 1039
One-way avoidance, 153
Ontogeny, 483, 1273
Ontogeny of dopamine function, 863
Ontogeny of ingestion, 863
Open field, 705
Operant behavior, 625
Operant extinction, 589
Opiate antagonist(s), 839, 1183
Opiate dependence, 1093
Opiate receptor, 187
Opiate tolerance, 1107
Opiate tolerance-dependence, 603
Opiate withdrawal, 357
Opiates, 799, 1033
Opioid(s), 1, 925, 1033, 1065, 1129, 1183
Oral activities, 329
Oral ethanol self-administration, 249
Oral stereotypy, 1217
Oxiracetam, 949, 1161
Oxygen consumption, 577, 1209
Oxytocin, 187, 491, 897, 1263

Pain, 193
Paired activity, 1183
Parasympathetic, 357
Paraventricular nucleus, 897
Parkinson's disease, 423
Passive avoidance, 139
Passive avoidance learning, 635
p-chloroamphetamine, 173
p-chlorophenylalanine, 173
PCPA, 871
Penicillin, 651
Pentobarbital, 223, 563, 1233
Peptide, 939
Peptide angiotensin II receptor antagonist, 229
Peripheral serotonin, 847, 943
Pertussis toxin, 723
Pharmacodynamics, 621
Phecyclidine, 61
Phenobarbital, 453
Phenobarbitone, 1053
Phenylethylamine, 749
Phenylpropanolamine, 1047
Phloridzin, 919
Phobia, 1195
Physical contact, 855
Physical dependence, 387
Physostigmine, 125, 483
Picrotoxin, 291
Pigs, 329, 347
Pilocarpine, 315
Pimozide, 979
Pirenperone, 1099
Place preference conditioning, 235
PMMA, 759
Polar bear, 199
Positive reinforcement, 495, 863
Postnatal stress response, 537
Prazosin, 111
Precipitated withdrawal, 1093
Preferential autoreceptor antagonists, 495
Prefrontal cortex, 17
Pregnanolone, 523
Prenatal, 1059
Prenatal environmental stress, 537
Prenatal psychological stress, 537
Preoptic area, 957
Prepulse inhibition, 1201
Primates, 369
Probucol, 1175
Proconvulsant drugs, 669
Proestrous female rats, 833
Progesterone, 523, 953
Propranolol, 577
Prostaglandins, 1169
Prostration/immobility syndrome, 1165
Psychotropics, 1155
Purinergic system, 673
Pyrogens, 1253

Quantitation, 381
Quinpirole, 249, 967, 1217

Rabbit, 651, 919
Radial maze, 645
Radioimmunoassay, 1107
Rat(s), 61, 77, 111, 167, 249, 303, 315, 321, 369, 503, 509, 577, 583, 631, 635, 689, 705, 729, 779, 785, 807, 871, 967, 1015, 1023, 1053, 1059, 1065, 1071, 1081, 1087, 1093, 1155, 1183, 1221, 1241
Rat lines, 825
Rearing, 125
Receptor, 413, 1273
Receptor reserve, 405
Reciprocal hindleg body scratch, 131
Recovery of function, 771
Reference memory, 645
Reinforcement, 377
Reinforcing effects, 463
Reproduction, 449
Respiration, 1227
Rest-activity cycle, 1059
Reversal phosphorylation, 999
Reward, 97, 377, 657
Ritanserin, 483, 961, 1241
Ro 15-4513, 97
Ro 19-6327, 549
Rotation, 795, 1151
RU 24969, 1273
RU 33965, 583

S-adenosyl-L-methionine, 423
Saliva, 513
Saralasin, 229, 729
Satiety, 847, 975
SCH 23390, 377, 967
Schedule-controlled responding, 509
Schedule-induced behavior, 689
Schedule-induced polydipsia, 255
Schedule induction, 45, 235
Schizophrenia, 1201
Scopolamine, 139, 617, 645, 657, 949, 1161
Sedation, 825
Seizure, 291
Selective breeding, 1015, 1233
Selective opioid agonists, 1209
Self-administration, 463, 563, 589
Sensitization, 1, 307, 815
Sensorimotor cortex, 771
Sensorimotor gating, 1201
Serotonergic analogs, 255
Serotonin, 17, 103, 361, 395, 483, 833, 847, 871, 929, 943, 1241, 1247, 1273
Serotonin autoreceptors, 953
Serotonin metabolism, 173
Serotonin receptors, 661, 1221
Serotonin syndrome, 131
Sex differences, 795
Sexual behavior, 181
Sexual dimorphism, 71, 441
Sham drinking, 847
Sham feeding, 847
Shaping, 589
6-OHDA, 887
SK&F 38393, 967, 993
Sleep, 939
Sleep time, 297, 1233
SND 919, 993
Snout contact fixation, 329
Social behavior, 1183
Social context, 463
Social interactions, 855
Social rank, 181
Social signals, 449
Sodium carbonate, 417
Somatostatin, 1165
Spatial learning, 91, 949, 1151
Spatial navigation, 167
Spiroperidol, 71
Spontaneous activity, 749, 1183
Squirrel monkeys, 613
Startle, 1201
Starvation, 733
Stereotyped behavior, 1217
Stereotypics, 329, 329
Stereotypy(ies), 17, 347
Steroid, 523
Stimulus control, 1221
Stimulus generalization, 739
Stimulus properties of drugs, 77, 1015, 1233
Strain differences, 795
Stress, 85, 677, 733
Stress coping, 255
Striatum, 603, 999
Subdiaphragmatic vagotomy, 919
Subiculum, 1201
Subjective drug effects, 563
Subtypes, 733
Successive discrimination, 589
Successive negative contrast, 153
Sulpiride, 369
Supraoptic nucleus, 897
Sweet taste, 863
Swine, 799
Sympathetic, 357
Sympathomimetics, 1047
Syrian hamster, 159

Tail-flick, 193
Tail-flick test, 1129
Tail skin temperature, 229
Talipexole, 993
Tannic acid, 271
Taste sensitivity, 513
Taste thresholds, 513
γ-vinyl GABA, 529
Temperature, 285
Temperature regulation, 1209
Testosterone, 1087
TFMPP, 739
Theophylline, 621
Therapeutic treatment, 661
Thermal dehydration, 1065
Thermogenesis, 117
Thermoregulation, 957, 1209
Thiobarbituric acid-reactive substances, 1175
THIP, 1121
3α-hydroxy-5α-pregnan-20-one, 523
Tiletamine, 1129
T lymphocytes, 85
T-maze, 1161
Tolerance, 193, 243, 1227
Tonic activity, 925
Transport, 271
Tremors, 423
Tryptophan hydroxylase, 999
Two-bottle paradigm, 589
2-deoxy-D-glucose antinociception, 1241
2,5-dimethoxy-4-ethoxy-amphetamine, 1117
2,5-dimethoxy-4-methylthio-amphetamine, 1117
2,4,5-trimethoxy-amphetamine, 1117
Two-stimuli test, 589
Tyrosine, 1047
Tyrosinehydroxylase, 423

UK-14,304, 697

Vagal tone, 357
Vagus nerve, 919
Vasopressin, 491, 897
Ventral tegmental area, 255, 815, 929
Ventrolateral midbrain central gray, 833
Ventrolateral nucleus accumbens, 929
Ventromedial hypothalamus, 833
Verapamil, 1093
Vertical and horizontal locomotion, 571
Vitamin B_{12}, 635
Vitamin C, 1175
Vitamin E, 1175
Vocalizations, 37
Voluntary wheel running, 285
VTA, 1, 657

Walking, 125
Water balance, 897, 1065
Water intake, 1065
Water maze, 785
Water maze task, 91
Wheel running, 159
Wistar rats, 589
Withdrawal, 243, 799
Withdrawal jumping, 1107
Woodchuck, 199
Working memory, 645
X-rays, 785
Xylazine, 1129

Yawning, 483, 673, 985
Yohimbine, 77, 449, 577, 1039, 1221

Zacopride, 1099
Zolazepam, 1129

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 43 1992

AUTHOR INDEX

Abe, E., 571
Adler, M. W., 1209
Agars, K., 657
Airaksinen, M. M., 683
Algeri, S., 949
Alliot, J., 1005
Altman, H. J., 453
Altug, T., 529
Ambler, D. L., 199
Amit, Z., 1121
Amstrup, S. C., 199
Antoniou, K., 705
Appel, J. B., 967
Arıcioğlu, F., 341, 479, 487
Armario, A., 598
Arya, A., 1247
Askanazi, J., 669
Azarov, A. V., 193

Babcock, A. M., 957
Badiani, A., 53
Baker, D. A., 957
Balboa, J. L., 85
Banks, W. A., 939
Bao, K., 625
Barney, C. C., 1065
Bartolini, L., 1161
Bass, P. P., 1107
Beck, B., 881
Becker, H. C., 1169
Becker, L. A., 37
Belmonte, A., 85
Berthold, III, C. W., 111
Billington, C. J., 1033
Björk, A., 661
Blackman, D. E., 689
Blau, S., 205
Bloch, E. F., 537
Block, R. I., 907
Bodnar, R. J., 1241
Bohmaker, K., 405
Borowski, T. B., 1
Boyeson, M. G., 771
Boyle, A. E., 1121
Braverman, K., 907
Britton, D. R., 369
Broderick, P. A., 929
Brown, P., 1151
Bruce, D. S., 199
Bruhat, M.-A., 1005
Bryson, R., 285
Buckley, M., 369
Budhram, P., 583
Burlet, A. J., 897
Burlet, C. R., 881, 897
Burton, L. E., 537
Büyükdevrim, S., 529
Byrnes, J. J., 413

Cabib, S., 53
Cade, J. R., 1143
Cain, D. P., 807
Caine, S. B., 1201
Calcagnetti, D. J., 1023
Caldarola-Pastuszka, M., 833
Candido, A., 153
Carlisle, H. J., 577
Carroll, F. I., 1135
Carter, V. A., 779
Cebeira, M., 603
Chalfin, M., 405
Chamberlin, J. R., 285
Chao, C., 799
Chapleur-Chateau, M., 897
Charles, M. A., 1087
Charlton, C. G., 423
Chen, R., 235
Cheng, P. Y., 1227
Cheng, Y., 1227
Cheskin, L. J., 357
Cho, C. H., 1053
Chrétien, R., 315
Church, A. C., 617
Church, S., 1059
Cleary, J., 1033
Coen, K. M., 1117
Cole-Harding, S., 563
Commissaris, R. L., 453, 471, 697
Connor, J. D., 1165
Correa-Sales, C., 723
Corrigall, W. A., 1117
Crowell, Jr., B., 423
Crowne, D. P., 795, 1151
Cunningham, C. L., 97, 307
Cunningham, J. S., 779
Currie, P. J., 1039
Curzon, P., 369

Da Cunha, C., 677
D'Amato, F. R., 181
Darmani, N. A., 765
Davies, M. F., 825
Davis, H. N., 37
De Carolis, A. S., 651
Decena, J. A., 1227
De Costa, B. R., 1135
Dennison, Z., 807
De Rosa, G., 329
Deutsch, S. I., 609
de Wit, H., 463, 563
Dizdar, Y., 341, 487
Dogaru, C., 1217
Dokla, C. P. J., 1183
Doty, P., 61
Dow-Edwards, D. L., 1059
Droge, M., 833
Dykstra, L. A., 61

Eberle-Wang, K., 847, 943
Eison, A. S., 131
Ellinwood, Jr., E. H., 243
Emoto, H., 729
Esin, Y., 479
Espinoza, M., 979, 1093

Falk, J. L., 45, 235
Falter, H., 315
Farinpour, R., 907
Ferguson, J. L., 785
Ferko, A. P., 297
Fernández-Guasti, A., 433
Fernández-Ruiz, J. J., 603
Ferré, N. S., 589
File, S. E., 1195
Fisher, M. C., 1241
Fitzhugh, E. C., 641
Flexner, J. B., 617
Flexner, L. B., 617
Flores, R., 979, 1093
Florio, T., 139
Fontana, D. J., 697
Fregly, M. J., 229, 1143
Freire-Garabal, M., 85
Frosini, M., 1253
Fujii, K., 985
Furukawa, T., 985, 993

Galpern, W. R., 413
García-Medina, M. R., 513
Gardner, C. R., 583
Garges, P. L., 103
Gayet, J., 173
Gayle, C., 863
Geiselman, P. J., 919
Geller, E. B., 1209
Georgiev, V., 729
Geyer, M. A., 1201
Ghanta, V., 417
Gibbs, J., 975
Gil, M., 597
Ginefri-Gayet, M., 173
Giry, N., 1005
Glennon, R. A., 739, 759, 1099
Gonzalez, R. A., 111
Gordon, C. J., 103
Grade, C. M., 771
Greenblatt, D. J., 413
Grette Lydon, R., 645
Grieg, N., 1135
Grimaldi, M., 139

Hadfield, M. G., 395
Hale, R. L., 1169
Hall, W. L., 271
Hamann, S. R., 925
Handler, C. M., 1209
Hanna, A. N., 1175
Harada, H., 215
Haraguchi, M., 249
Hasegawa, H., 1269
Hashimoto, H., 215
Hashimoto, S., 503
Head, E., 749
Hennessy, M. B., 37
Henschel, T. M., 199
Hernández, M. L., 603
Hernandez, T. D., 17
Herndon, J. L., 739
Higgs, R., 759, 1099
Hiramoto, N., 417
Hiramoto, R., 417
Hiroi, N., 377
Hitzemann, R., 871
Hodge, C. W., 249
Hoffman, A., 621
Holmgren, B., 483
Holtman, J. R., 925
Hooks, M. S., 815
Hsueh, C.-M., 417
Hudzik, T. J., 509
Hughes, R. N., 125
Hull, K. M., 1047
Hutchings, D. E., 1059

Ikarashi, Y., 635
Illius, A. W., 329, 347
Inano, S., 673
Insel, T. R., 855
Ishii, Y., 985
Issa, H., 1099
Itoh, T., 571
Itsukaichi, O., 571
Izquierdo, I., 677

Jaffe, K., 205
Jakubow, J., 847
Jaskiw, G. E., 1247
Jaspan, J. B., 939
Jellum, E., 669
Jenkins, R., 37
Jhanwar-Uniyal, M., 897
Jin, Z. L., 117
Jodogne, C. M., 1263
Johanson, C.-E., 463
Jones, C. S., 641
Jones, G. H., 17, 815, 887
Joyner, C. J., 243
Justice, Jr., J. B., 815

Kafetzopoulos, E., 705
Kaneyuki, H., 673
Kanit, L., 71
Kasahara, K.-I., 503
Kastin, A. J., 939
Kauffman, E. M., 1175
Kendall, D. A., 17
Kim, A., 1135
Kimura, H., 985, 993
King, G. R., 45, 243
Kling-Petersen, T., 495
Kokka, N., 441
Kokkinidis, L., 1, 657
Kopchia, K. L., 453
Kovács, G. L., 187, 491
Koya, R., 677
Koyuncuoğlu, H., 341, 479, 487
Kozlachkova, E. Y., 999
Kramer, G., 361
Krieger, N. R., 523
Krimmer, E. C., 1233
Kriván, M., 187
Krobert, K. A., 771
Kuczenski, R., 1075
Kudrin, V. S., 683
Kuhn, C., 243
Kulikov, A. V., 999

Ladewig, J., 329
Lake, J. R., 779
Lang, C. M., 1129
Lanier, J. G., 779
Lankford, M., 661
Larach, D. R., 1129
Lattin, D. L., 509
Lau, C. E., 45, 235
Lawrence, A. B., 329, 347
Lee, T. F., 117
Lee, T. H., 243
Legros, J.-J., 1263
Leibowitz, S. F., 897
Leidenheimer, N. J., 77
Leon, B. A., 483
Levi De Stein, M., 677
Levine, A. S., 1033
Liem, B. J., 815
Lipska, B. K., 1247
Lodge, B. A., 1117
Loew, G. H., 825
López-Rubalcava, C., 433
Lu, C. C., 255
Lu, M.-S., 387

Maguire, P. A., 825
Maher, T. J., 1047
Maisky, A. I., 683
Maldonado, A., 153
Malin, D. H., 779
Malloy, L. C., 263
Malott, D. H., 97
Malowany, D., 1059
Manner, T., 669
Marino, A., 139
Marsden, C. A., 17
Marti, J., 597
Martin, B. R., 381
Martin, W. R., 925
Maruyama, Y., 635
Mastropaolo, J., 609
Masuda, Y., 571
Matsumoto, S.-I., 985, 993
Matsuzaki, Y., 635
Mattes, R. D., 513
Maze, M., 723
Mazurkiewicz, M., 91
McGinnis, M. Y., 1087
McMillan, D. E., 509
McNaughton, N., 167
Medina, J. H., 677
Megias, J. L., 153
Meguro, K., 635
Mela, D. J., 513
Melchior, C. L., 223
Meller, E., 405
Melnik, E. I., 683
Melville, L. D., 975
Messiha, F. S., 1071
Meucci, O., 139
Meyer, M. E., 303
Michaleva, I. I., 683
Mickley, G. A., 785
Middaugh, L. D., 625
Milgram, N. W., 749
Milio, C., 395
Miller, D. B., 103
Miller, L. G., 413
Miroshnicenko, T. I., 683
Misawa, M., 387
Missaghi, B., 1081
Mistlberger, R. E., 159
Mizuki, Y., 673
Moerschbaecher, J. M., 111
Mok, W. M., 523
Molitor, T. W., 799
Mollenauer, S., 285
Moody, T. W., 957
Morales, A., 153
Morniroli, G., 1071
Morpurgo, B., 449
Morris, R. G. M., 167
Morrison, C. M., 1065
Motegi, H., 387
Murai, S., 571
Murtaugh, M. P., 799
Myers, R. D., 661

Nadal, R. A., 589
Nadeau, J., 159
Nadzan, A., 369
Nagashima, M., 985, 993
Nagatani, T., 503
Nakajima, S., 645
Nakajima, T., 215
Nakamura, M., 1269
Nauton, P., 1005
Navarro, M., 603
Nemeth, T. J., 785
Newlin, D. B., 357
Newlin-Maultsby, P., 779
Newman, H. A. I., 1175
Nicholson, M. E., 641
Nicolas, J. P., 881
Nilekani, S. P., 199
Noble, D., 307
Norris, D. O., 609
Noto, T., 215
Novitzki, M. R., 609
Novotny, M. F., 795
Núñez, M. J., 85

O'Connor, D. A., 609
Oeltgen, P. R., 199
Ogle, C. W., 1053
Ohkubo, N., 571
Okuda, C., 1075
Okur, B. E., 71
Olsen, R. W., 441
Olson, K. G., 1107
Onaivi, E. S., 825
O'Neil, D. R., 37
Ortiz, S., 1093
Ossenkopp, K. P., 807
Özkan, T., 529

Pallarées, M. A., 589
Palmi, M., 1253
Palumbo, P. A., 1221
Parker, F. L., 583
Pasi, A., 1071
Pavone, F., 181
Pellon, R., 689
Pepeu, G., 1161
Persinger, M. A., 315, 1081
Pert, A., 1135
Petersen, A. J., 669
Peterson, P. K., 799
Petty, F., 361
Pezzola, A., 651
Picker, M. J., 61
Pierson, M. E., 739
Pirke, K. M., 733
Pitsikas, N., 949
Pögün, S., 71
Popova, N. K., 999
Porter, J. H., 961
Postiglione, A., 139
Pranzatelli, M. R., 1273
Prescott, W. R., 381
Pugh, G., 1107
Puglisi-Allegra, S., 53
Purali, N., 529

Qiu, B. S., 1053

Ramos, J. A., 603
Randall, C. L., 1169
Rayevsky, K. S., 683
Reid, K., 723
Renkema, L.-A., 1065
Rezvani, A. H., 103
Rice, K. C., 1135
Richards, P. M., 1081
Riekkinen, P. J., 91
Riley, A. L., 97, 839
Risaliti, R., 1161
Risdahl, J. M., 799
Risinger, F. O., 97
Ritzmann, R. F., 223
Robbins, T. W., 17, 887
Roberts, L. K., 779
Robertson, J. M., 1117
Robinzon, B., 449
Rochford, J., 321
Rodriguez, R., 1155
Rodriguez De Fonseca, F., 603
Rogerio, R., 631
Rogers, C., 417
Rothman, R. B., 1135
Rowland, N. E., 229, 1143
Rozenboim, I., 449
Rudski, J. M., 1033

Sagratella, S., 651
Salamanca, S., 953
Saldívar, A., 433
Samson, H. H., 249
Sanderson, J. D., 919
Saouda, F. M., 1117
Sapp, D. W., 441
Sarnyai, Z., 187, 491
Sasaki, H., 635
Sayin, Ü., 487, 529
Schaal, D. W., 1033
Schechter, M. D., 77, 1015, 1023
Scherer, P. J., 771
Schettini, G., 139
Schiffman, S. S., 271
Schnur, P., 979, 1093
Schweiger, U., 733
Scorziello, A., 139
Segal, D. S., 1075
Seidman, M. H., 235
Sekizawa, K., 635
Sgaragli, G., 1253
Sharma, H. M., 1175
Shelnutt, S., 509
Shepherd, C. L., 625
Shoji, S., 571
Simansky, K. J., 847, 943
Simon, S. A., 271
Sirviö, J., 91
Sisk, F. C., 847
Skeie, B., 669
Slate, S. O., 263
Smith, B. R., 1121
Smith, G. P., 863, 975
Smurthwaite, S. T., 839
Sobrian, S. K., 537
Spealman, R. D., 613
Speck, C., 285
Steen, P. A., 669
Stewart, J., 321
Storrie-Baker, H. J., 795
Stricker-Krongrad, A., 881
Sullivan, R., 1217
Suzuki, T., 387
Svensson, K., 495
Svingos, A. L., 871
Swerdlow, N. R., 1201
Szabó, G., 187, 193, 491
Szechtman, H., 1217
Szeto, H. H., 1227

Taga, C., 215
Takahashi, R. N., 631
Takao, K., 503
Tanaka, M., 729
Tanimura, S., 513
Telegdy, G., 187, 193, 491
Tennilä, T. M.-L., 683
Terlouw, E. M. C., 329, 347
Thompson, T., 1033
Tirelli, E., 1263
Tokrud, P. A., 1151
Torres, M. D. C., 153
Tsai, N. F., 825
Tseng, C. J., 255
Tsuda, A., 729
Tsuji, M., 215
Tufano, M., 369
Tung, C. S., 255
Turner, K. P., 1169
Tyrka, A., 863

Ugarte, A., 483
Uhde, T. W., 263
Ukita, T., 673
Uphouse, L., 833, 953
Urbä-Holmgren, R., 483
Üresin, Y., 479
Ushakov, A. N., 683
Ushijima, I., 673

Vaidya, A. H., 847
Vallejos, S., 1093
Van der Weele, D. A., 919
Van Groll, B. J., 967
Van Hartesveldt, C., 303
Vaughn, V. T., 537
Velíšek, L. S., 291
Velíšková, J., 291
Ventra, C., 139
Vergoth, C., 1065

Wada, Y., 1269
Wainwright, M., 1093
Wan, F. J., 255
Wang, L. C. H., 117
Wang, M. Q., 641
Weinberger, D. R., 1247
Welch, S. P., 1107
Westerfield, C. R., 641
White, N. M., 377
Wilckens, T., 733
Wiley, J. L., 961
Williams, M. T., 37
Williams, Y. Z., 1165
Wilson, L., 361
Wilson, L. M., 1039
Wilson, O. B., 779
Wilson, R. P., 1129
Winslow, J. T., 855
Winter, J. C., 1221
Witt, D. M., 855
Witte, U., 441
Wolfman, C., 677
Wollnik, F., 549
Wong, C. J., 357
Wright, R. N., 131
Wu, D.-L., 1227

Xie, Z., 471

Yahiro, L., 369
Yamada, K., 985, 993
Yamada, M., 673
Yamaguchi, N., 1269
Yamaguchi, S., 635
Yin, T. H., 255
Yoshi, T., 387
Yoshida, S., 985
Young, R., 1099
Yukhananov, R. Y., 683

Zabala, N. A., 205
Zagon, I. S., 1129
Zangrossi, Jr., H., 1195
Zeng, Y. C., 651
Zhu, M., 381
Zmitrovich, A. C., 1059
Zylan, K. D., 577